相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Epigenetic dynamics in cancer stem cell dormancy
Alejandra I. Ferrer et al.
CANCER AND METASTASIS REVIEWS (2020)
EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties
Yongfei Li et al.
FASEB JOURNAL (2019)
Breast cancer stem cells are involved in Trastuzumab resistance through the HER2 modulation in 3D culture
Cristina E. Rodriguez et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
Francesco Schettini et al.
CANCER TREATMENT REVIEWS (2016)
Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer
Eylem Kulkoyluoglu et al.
STEROIDS (2016)
Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7 tumorspheres by inhibiting the drug efflux function of ABC transporters
So-Young Chun et al.
BIOMEDICINE & PHARMACOTHERAPY (2015)
Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1
Yun-Suk Kwon et al.
ONCOLOGY REPORTS (2015)
Cancer stem cell plasticity and tumor hierarchy
Marina Carla Cabrera et al.
WORLD JOURNAL OF STEM CELLS (2015)
Tumorsphere assay provides more accurate prediction of in vivo responses to chemotherapeutics
Soyoung Kim et al.
BIOTECHNOLOGY LETTERS (2014)
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
Pernelle Lavaud et al.
BMC MEDICINE (2014)
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
Branka Petricevic et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Cytoplasmic Estrogen Receptor in Breast Cancer
Allison W. Welsh et al.
CLINICAL CANCER RESEARCH (2012)
Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties
Linlin Zhang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Slow-Cycling Therapy-Resistant Cancer Cells
Nathan Moore et al.
STEM CELLS AND DEVELOPMENT (2012)
Trastuzumab: updatedmechanisms of action and resistance in breast cancer
Thuy Vu et al.
FRONTIERS IN ONCOLOGY (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Quiescent, Slow-Cycling StemCell Populations in Cancer: A Review of the Evidence and Discussion of Significance
Nathan Moore et al.
JOURNAL OF ONCOLOGY (2011)
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation
Yen-Chao Wang et al.
BREAST CANCER RESEARCH (2011)
Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
Guanglei Zhuang et al.
CANCER RESEARCH (2010)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
Merel Gijsen et al.
PLOS BIOLOGY (2010)
Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations
Debbie C. Koay et al.
BREAST CANCER RESEARCH (2010)
Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells
Bin Chen et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2008)
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers
Minjie Wei et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: Tamoxifen-bound reactivated ER recruits distinctive corepressor complexes
D Sharma et al.
CANCER RESEARCH (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
In vitro and in vivo effects of combination of trastuzumab (Herceptin) and tamoxifen in breast cancer
CX Wang et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Synergistic interactions between tamoxifen and trastuzumab (Herceptin)
A Argiris et al.
CLINICAL CANCER RESEARCH (2004)
Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells
YH Lu et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
HER2 expression in breast cancer primary tumours and corresponding metastases.: Original data and literature review
J Carlsson et al.
BRITISH JOURNAL OF CANCER (2004)
P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report
C Vogel et al.
EUROPEAN JOURNAL OF CANCER (2001)
Estrogen receptor α rapidly activates the IGF-1 receptor pathway
S Kahlert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
